Cannabinoid receptor genes

Progress in Neurobiology

Volumn 48, Issue 4-5, 1996, Pages 275-283

  Onaivi, Emmanuel S ^a   Chakrabarti, Amitabha ^a   Chaudhuri, Gautam ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; NABILONE; PROTEIN KINASE; RECEPTOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL TISSUE; BEHAVIOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RECEPTOR BINDING; REVIEW;

EID: 0030008428     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-0082(95)00044-5     Document Type: Review

References (121)

1. Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G. and Makriyannis, A. (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889-1893.
2. Abood, M. E. and Martin, B. R. (1992) Neurobiology of marijuana abuse. Trends Phamacol. Sci. 13, 201-206.
3. Aceto, M. D., Martin, B. R., Scates, S. M. and Lowe, J. (1995) Cannabinoid precipitated withdrawal: Induction by the antagonist SR141716A. Faseb J. 9, 3, 2320.
4. Bach, D., Raz, A. and Goldman, R. (1976) The effect of hashish compounds of phospholipid phase transition. Biochim. Biophys. Acta. 436, 889-894.
5. Bhargava, H. N. (1978) Potential therapeutic applications of naturally occuring and synthetic cannabinoids. Gen. Pharmacol. 9, 195-213.
6. Bidaut-Russel, M., Devane, W. A. and Howlett, A. C. (1990) Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55, 21-26.
7. Binder, M. and Franke, I. (1982) Is there a THC receptor? Current perspectives and approaches to the elucidation of the molecular mechanisms of action of the psychotropic constituents of Cannabis sativa L. In: Neuroreceptors, pp. 151-156. Eds. Walter de Gruyter, Berlin.
8. Binder, M., Edery, H. and Porath, G. (1979) Delta-7-tetrahydrocannabinol, a non-psychotropic cannabinoid: structure activity considerations in the cannabinoid series. In: Marijuana: Biological effects, pp. 71-80. Eds. G. G. Nahas and W. D. M. Paton, Pergamon Press, Oxford.
9. Bornheim, L. M., Kim, K. Y., Chen, B. and Correia, M. A. (1993) The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem. Biophys. Res. Commun. 197, 740-746.
10. Bouaboula, M., Rinaldi, M., Carayon, P., Carrilon, C., Delpech, B., Shire, D., Le Fur, G. and Casellas, P. (1993) Cannabinoid receptor expression in human leukocytes. Eur. J. Biochem. 214, 173-180.
11. Bramblett, R. D., Panu, A. M., Ballesteros, J. A. and Reggio, P. H. (1995) Construction of a 3D model of the cannabinoids CB1 receptor: Determination of helix ends and helix orientation. Life Sci. 56, 1971-1982.
12. Bruggemann, E. P. and Melchior, D. L. (1983) Alterations in the organization of phosphatidylcholine/cholestrol bilayers by tetrahydrocannabinol. J. Biol. chem. 258, 8298-8303.
13. Burstein, S. and Hunter, S.A. (1984a) The biochemistry of the cannabinoids. Rev. Pure Appl. Pharmacol. Sci. 2, 155-226
14. Burstein, S. and Hunter, S. A. (1984b) The role of prostaglandins in the actions of the cannabinoids. In: The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects, pp. 729-738 Eds. S. Agurell, W. L. Dewey and R. E. Willette, Acad. Press, Orlando.
15. Burstein, S. H., Audette, C. A., Charalambous, A., Doyle, S. A., Guo, Y., Hunter, S. A. and Makriyannis, A. (1991) Detection of cannabinoid receptors by photoaffinity labelling. Biochem. Biophy. Res. Comm. 176, 492-497.
16. Caulfield, M. P. and Brown, D. A. (1992) Cannabinoid receptor agonist inhibit Ca current in NG108-15 neuroblastomer cells via a Pertussis toxin-sensitive mechanism. Brit. J. Pharmac. 106, 231-232.
17. Chakrabarti, A., Onaivi, E. S. and Chaudhuri, G. (In press, 1995) Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Sequence.
18. Cohen, S. and Stillman, R. C. (Eds.) (1976) The therapeutic potential of marijuana. Plenum Med. Book Co. New York.
19. Compton, D. R., Gold, L. H., Ward, S. J., Balster, R. L. and Martin, B. R. (1992) Aminoalkylindolen analogs: cannabinomimetic activity of a class of compounds structurally distinct from delta-9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263, 1118-1126.
20. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A. and Axelrod, J. (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypermotility and hypothermia in viro in rodents. Pharmacol. Biochem. Behav. 46, 967-972.
21. Crooke, S. T. (1992) Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376.
22. Das, S. K., Paria, B. C., Chakraborty, I. and Dey, S. K. (1995) Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sci. 92, 4332-4336.
23. 9-THC on body temperature in mice. Psychopharmacol. 69, 229-305.
24. Deutsch, D. G. and Chin, S. A. (1993) Enzymatic synthesis of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796.
25. Devane, W. A. (1994) New dawn of cannabinoid pharmacology. Trends Pharmacol. Sci. 15, 40-41.
26. Devane, W. A. and Axelrod, J. (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. U.S.A. 91, 6698-6701.
27. Devane, W.A., Breuer, A., Sheskin, T., Jarbe, T.U.C., Eisen, M.S. and Mechoulam, R. (1992a) A novel probe for the cannabinoid receptor. J. Med. Chem. 35, 2065-2069.
28. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992b) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
29. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. and Howlett, A. C. (1988) Determination and characterization of cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613.
30. Dewey, W. L. (1986) Cannabinoid pharmacology. Phamarcol. Rev. 38, 151-178.
31. Di Marzo, V., Fontana, A., Cadas, H., Scinelli, S., Cimino, G., Schwartz, J. C. and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
32. Edelman, A. E., Blumental, D. K. and Krebs, E. G. (1987) Protein serine/threonine kinases. Ann. Rev. Biochem
33. Fabre, L. F. and McClendon, D. (1981) The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J. Clin. Pharmacol. 21, 377S-382S.
34. Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D. and Leon, A. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. natl. Acad. Sci. U.S.A. 92, 3376-3380.
35. Fairbain, J. W. and Pickens, J. T. (1979) The oral activity of Δ1-THC and its dependence on prostaglandin E2. Brit. J. Pharmacol. 67, 379-385.
36. Fan, P. (1995) Cannabinoid agonist inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73, 907-910.
37. Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M. and Matsuda, L. A. (1992) Cannabinoid agonists stimulate both receptor- and non-receptor mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Molec. Pharmacol. 42, 838-845.
38. Fishman, S. M., Rosenbaum, J. F., Yabusaki, D. I. and Carr, D. B. (1988) Marijuana relaxed anxiety: A questionaire based pilot study of normal and psychiatric populations. Res. Commun. Substance Abuse, 9, 219-226.
39. Foltin, R. W. and Fischman, M. W. (1988) Effects of smoked marijuana on human social behavior in small groups. Pharmacol. Biochem. Behav. 30, 539-541.
40. Formukong, E. A., Evans, A. T. and Evans, F. J. (1989) The medicinal uses of cannabis and its constituents. Phytotherapy Res. 3, 219-231.
41. Fride, E. and Mechoulam, R. (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constitutent. Eur. J. Pharmacol. 231, 313-314.
42. Fride, E., Barg, J., Levy, R., Saya, D., Heldman, E., Mechoulam, R. and Vogel, Z. (1995) Low doses of anandamides inhibit pharmacological effects of delta-9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272, 699-707.
43. Gerard, C. M., Mollereau, C., Vassart, G. and Parmentier, M. (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279, 129-134.
44. Glass, R. M., Uhlenhuth, E. H., Hartel, F. W., Schuster, C. R. and Fischman, M. W. (1975) Single-dose study of nabilone in anxious volunteers. J. Clin. Pharmacol. 21, 383-396.
45. Green, M. R. (1991) Biochemical mechanisms of constitutive and regulated pre-mRNA splicing. Annu. Rev. Cell Biol. 7, 559-599.
46. 9-THC during oral surgery. J. Oral Surg. 34, 301-313.
47. Halikas, J. A., Weller, R. A., Mouse, C. L. and Hoffman, R. A. (1985) A longitudinal study of marijuana effects. Int. J. Addict, 20, 701-711.
48. Harris, L. S., Carchman, R. A. and Martin, B. R. (1978) Evidence for the existence of specific cannabinoid binding sites. Life Sci. 22, 1131-1138.
49. Helene, C. and Toulme, J. J. (1990) Specifc regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049, 99-125.
50. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R. and Rice, K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
51. Hillard, C. J. and Auchampach, J. A. (1994) In vitro activation of brain protein kinase C by the cannabinoids. Biochim. Biophys. Acta. 1220, 163-170.
52. Hillard, C. J., Harris, R. A. and Bloom, A. S. (1985) Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: Fluorescence studies. J. Pharmac. Exp. Ther. 232, 579-588.
53. Hollister, L. E. (1986) Health aspects of cannabis. Pharmacol. Rev. 38, 1-20.
54. Howlett, A. C., Johnson, M. R., Melvin, L. S. and Milne, G. M. (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid model. Molec. Pharmac. 33, 297-302.
55. Iversen, L. L. (1993) Medical uses of marijuana?. Nature 365, 12-13.
56. Jansen, E. M., Haycock, D. A., Ward, S. J. and Seybold, V. S. (1992) Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575, 93-102.
57. Johnson, D. E., Heald, S. L., Dally, R. D. and Janis, R. A. (1993) Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1, 4-dihydropyridine binding. Prostaglandins Leukot. Essent. Fatty Acids. 48, 429-437.
58. 9-THC. Psychopharmacol. 33, 53-70.
59. 9-THC in man. Eur. J. Pharmacol. 28, 172-177.
60. Kim, S. K. and Wold, B. J. (1985) Stable reduction in thymidine kinase activity in cells expressing high levels of antisense RNA. Cell 42, 129-138.
61. 9-THC depressant effect by cannabinol in mice. Amer. J. Pharm. 143, 149-152.
62. Kruszka, K. K. and Gross, R. W. (1994) The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J. Biol. Chem. 269, 14345-14348.
63. Kuster, J. E., Stevenson, J. I., Ward, S. J., D' Ambra, T. E. and Haycock, D. A. (1993) Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol Exp. Ther. 264, 1352-1363.
64. Lambowitz, A. M. and Belfort, M. (1993) Introns as mobile genetic elements. Annu. Rev. Biochem. 62, 587-622.
65. 1-THC and other cannabinoids on spin labeled liposomes and their relationship to mechanism of general anesthesia. Mol. Pharmcol. 11, 595-602.
66. Lemberger, L. (1980) Potential therapeutic usefulness of marijuana. Annu. Rev. Pharmacol. Toxicol. 20, 151-157.
67. Leuschner, J. T. A., Wing, D. R., Harvey, D. J., Brent, G. A., Dempsey, C. E., Watts, A. and Paton, W. D. M. (1984) The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity. Experientia 40, 886-888.
68. 9-THC in the rat. Drug Alcohol Depend. 8, 93-101.
69. Li, H. C. (1974) An archeological and historical account of cannabis in China. Econ. Bot. 28, 437-448.
70. Mackie, K. and Hille, B. (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. natn. Acad. Sci. 89, 3825-3829.
71. Mackie, K., Devane, W. A. and Hille, B. (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498-503.
72. MacVector sequence analysis software (1994) Users manual, Scientific imaging systems, Rochester, New York.
73. Makriyannis, A., Banijamali, A., Jarrell, H. C. and Yang, D.-P. (1989) The orientation of (-)-delta 9-tetrahydrocannabinol in DPPC bilayers as determined by solid state 2H-NMR. Bichim. Biophys. Acta. 986, 141-145.
74. 9-THC: effects of ventillatory control and cardiovascular dynamics. Anesthesiology 42, 666-673.
75. Maniatis, T. (1991) Mechanisms of alternative pre-mRNA splicing. Science 251, 33-34.
76. Martin, B. R. (1986) Cellular effects of cannabinoids. Pharmacol. Rev. 38, 45-74.
77. Martin, B. R., Childers, S., Howlett, A., Mechoulam, R. and Pertwee, R. (1994) Cannabinoid receptors: Pharmacology, second messenger systems and endogenous ligands. NIDA Res. Monograph 140, 55-60.
78. Matsuda, L. A., Bonner, T. I. and Lolait, S. J. (1993) Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327, 535-550.
79. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. and Bonner, T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
80. Mattes, R. D., Engelman, K., Shaw, L. M. and Elsohly, M. A. (1994) Cannabinoids and appetite stimulation. Pharmacol. Biochem. Behav. 49, 187-195.
81. Melton, D. A. (1985) Injected antisense RNAs specifically block messenger RNA translation in vivo. Proc. natl. Acad. Sci. USA 82, 144-148.
82. Meyer, R. E, (1978) Behavioral pharmacology of marijuana. In: Psychopharmacology, a generation of progress, pp. 1634-1652. Eds. M. A. Lipton, A. Dimascio, K. F. Killam, Raven press, New York.
83. Milne, G. M., Johnson, M. R., Wiseman, E. H. and Hutcheon, D. E. (1981) Therapeutic progress in cannabinoid research. J. Clin. Pharmacol. 21, 34-47.
84. Mirabelli, C. K., Bennett, C. F., Anderson, K. and Crooke, S. T. (1991) In vitro and in vivo activities of antisense oligonucleotides. Anti-cancer drug design 6, 647-661.
85. Moss, D. E., McMaster, S. B. and Rogers, J. (1981) Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol. Biochem. Behav. 15, 779-783.
86. Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
87. Nye, J. S., Seltzman, H. H., Pitt, C. G. and Snyder, S. H. (1985) High affinity cannabinoid binding sites in brain membranes labeled with [3H]-5′-trimethylammonium delta-8-tetrahydrocannabinol. J. Pharmac. Exp. Ther. 234, 784-791.
88. O'Dowd, B. F. (1993) Structures of dopamine receptors. J. Neurochem. 60, 804-816.
89. Onaivi, E. S., Chakrabarti, A., Gwebu, E. T. and Chaudhuri, G. (In press, 1996) Neurobehavioral specificity of cannabinoid receptor gene expression in mice. Behav. Brain Res.
90. Onaivi, E. S., Green, M. R. and Martin, B. R. (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253, 1002-1009.
91. Pacheco, M., Childers, S. R., Arnold, R., Casiano, F. and Ward, S. J. (1991) Aminoalkylindoles: Actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257, 170-183.
92. Pertwee, R. G., Stevenson, L. A. and Griffin, G. (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabinomimetic agents, CP 55, 940, WIN 55, 212-2 and anandamide. Brit. J. Pharmacol. 110, 1483-1490.
93. Pertwee, R.G., Fernando, S.R., Griffin, G., Abadji, V. and Makriyannis, A. (1995a) Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 272, 73-78.
94. Pertwee, R., Griffin, G., Fernando, S., Li, X. and Makriyannis, A. (1995b) AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56, 1949-1955.
95. Pertwee, R., Griffin, G., Hanus, L. and Mechoulam, R. (1994) Effects of two endogenous fatty acid ethanolamides on mouse vas deferentia. Eur. J. Pharmacol. 259, 115-120.
96. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V. and Wadleigh, R. G. (1991) Recent clinical experience with dronabinol. Pharmacol. Biochem. Behav. 40, 695-700.
97. Priller, J., Briley, E. M., Mansouri, J., Devane, W. A., Mackie, K. and Felder, C. C. (1995) Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptor. Molec. Pharmacol. 48, 288-292.
98. Rademacher, T. W., Parekh, R. B. and Dwek, R. A. (1988) Glycobiology. Ann. Rev. Biochem. 57, 785-838.
99. Razdan, R. J. (1986) Stucture-activity relationships in cannabinoids. Pharmacol. Rev. 38, 75-149.
100. Razdan, R. K. and Howes, J. F. (1983) Drugs related to tetrahydrocannabinol. Med. Res. Rev. 3, 119-146.
101. Reynolds, R. (1980) On the therapeutic uses and toxic effects of cannabis sativa. Lancet 1, 637-638.
102. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C. and Le Fur, G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS lett. 350, 240-244.
103. Rio, D. C. (1992) RNA binding proteins, splice site selection, and alternative pre-mRNA splicing. Gene Expr. 2, 1-5.
104. 9-THC and the effects of various solubilizers. J. Pharm. Pharmacol. 31, 224-230.
105. Schuel, H., Goldstein, E., Mechoulam, R., Zimmerman, A. M. and Zimmerman. S. (1994) Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl. Acad. Sci. U.S.A. 91, 7678-7682.
106. Schwarz, H., Blanco, F. J. and Lotz, M. (1994) Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmuno. 55, 107-115.
107. Smart, R. G. and Adlaf, E. M. (1982) Adverse reactions and seeking medical treatment among student cannabis users. Drug Alcohol Depend. 9, 201-211.
108. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R. and Martin, B. R. (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219-227.
109. Souilhac, J., Poncelet, M., Rinaldi-Carmona, M., Le Fur, G. and Soubrie, P. (1995) Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51, 3-7.
110. Strader, C. D., Fong, T. M., Tola, M. R., Underwood, D. and Dixon, R. A. F. (1994) Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 63, 101-132.
111. Stubbs, L., Chittenden, L., Chakrabarti, A and Onaivi E. S. (1995) The mouse cannabinoid receptor gene is located in proximal chromosome 4. Mammalian Genome. In Press.
112. Synder, H. (1971) The uses of marijuana. Oxford University Press, Oxford.
113. 1H-NMR spectra of model membranes. J. Pharm. Sci. 72, 458-461.
114. Van der Kloot, W. (1994) Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction. Brain Res. 649, 181-184.
115. Vela, G., Ruiz-Gayo, M. and Fuentes, J. A. (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacol. 34, 665-668.
116. Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E. and Mechoulam, R. (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61, 352-355.
117. Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F. and Heilig, M. (1993) Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259, 528-531.
118. Weidenfeld, J., Feldman, S. and Mechoulam, R. (1994) Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary axis in the rat. Neuroendocrinol. 59, 110-112.
119. Welch, S. P., Dunlow, L. D., Patrick, G. S. and Razdan, R. K. (1995) Characterization of anandamide- and fluoroanandamide-induced antinociception and cross- tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273, 1235-1244.
120. Wiley, J., Balster, R. and Martin, B. (1995) Discriminative stimulus effects of ananadamide in rats. Eur. J. Pharmacol. 276, 49-54.
121. 9-THC in normal subjects. Psychopharmacology 76, 245-250.